Evoke Pharma (EVOK) Q1 2025 earnings summary

Executive summary

• Net product sales for Q1 2025 rose 77% year-over-year to $3.1 million, driven by increased prescriber adoption, repeat patient use, and expanded pharmacy network, with Eversana as commercial partner.

• Net loss narrowed to $1.3 million ($0.51 per share) in Q1 2025 from $1.6 million ($2.09 per share) in Q1 2024.

• Cash and cash equivalents were $12.6 million as of March 31, 2025, expected to fund operations into Q2 2026, but management has substantial doubt about ability to continue as a going concern beyond that without new funding.

• Fill rate increased 73% and total prescriber base grew 44% compared to Q1 2024, reflecting strong commercial execution.

• Eversana partnership includes a $5 million revolving credit facility; both parties may terminate the agreement if net profits remain negative for two consecutive quarters.

Financial highlights

• Net product sales: $3.1 million in Q1 2025 vs. $1.7 million in Q1 2024, driven by expanded pharmacy network and higher refill rates.

• Net loss: $1.3 million in Q1 2025 vs. $1.6 million in Q1 2024.

• Selling, general, and administrative expenses increased 37% year-over-year to $4.3 million, mainly due to higher marketing and Eversana profit sharing.

• Cash used in operating activities was $1.0 million in Q1 2025, compared to $2.6 million in Q1 2024.

• Research and development expenses were $42,783 in Q1 2025, up from $4,645 in Q1 2024.

Outlook and guidance

• 2025 net product sales guidance reiterated at $16 million, a 60% increase over 2024, dependent on business trends, reimbursement, and external factors.

• Current cash and expected Gimoti sales projected to fund operations into Q2 2026, but additional capital will be needed to continue as a going concern.

• Company anticipates continued operating losses due to commercialization activities and planned clinical trials for lower dose Gimoti.

• If Eversana terminates the agreement due to negative net profits, company would need to repay $7.2 million in debt and establish its own commercial infrastructure.